Bristol Myers Squibb (BMY) Share-based Compensation (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Share-based Compensation data on file, last reported at $146.0 million in Q1 2026.

• Quarterly Share-based Compensation rose 1.39% year-over-year to $146.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $555.0 million (up 7.14% YoY) and the FY2025 annual result came in at $553.0 million, up 9.07% from the prior year.
• Share-based Compensation grew to $146.0 million in Q1 2026 per BMY's latest filing, from $133.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $146.0 million in Q1 2026 and bottomed at $107.0 million in Q1 2022.
• The 5-year median for Share-based Compensation is $129.0 million (2024), against an average of $128.3 million.
• The widest annual swing landed in 2022, when Share-based Compensation dropped 29.14%; it then rose 18.1% in 2023.
• Tracing BMY's Share-based Compensation over 5 years: stood at $119.0 million in 2022, then rose by 6.72% to $127.0 million in 2023, then slipped by 5.51% to $120.0 million in 2024, then climbed by 10.83% to $133.0 million in 2025, then rose by 9.77% to $146.0 million in 2026.
• Per Business Quant, the three latest BMY Share-based Compensation figures stand at $146.0 million (Q1 2026), $133.0 million (Q4 2025), and $139.0 million (Q3 2025).

Peer Comparison